Hana Asset Management announced on August 6 that the net asset value of the '1Q US Medical AI ETF,' which was listed on July 22, has surpassed 20 billion KRW.
Individual investors have continued net purchases of the 1Q US Medical AI ETF for 11 consecutive trading days since its listing, up to the previous day. The cumulative net purchase amount has reached approximately 14 billion KRW. Among overseas healthcare/bio ETFs listed in Korea, it ranks first in net purchases by individual investors.
The 1Q US Medical AI ETF invests in a total of 15 US-listed companies expected to benefit from the growth of the medical (healthcare) AI industry. It allocates 25%, 15%, and 10% of its portfolio to Tempus AI, an AI-based precision medicine (diagnostics) platform company known as the 'Palantir of Healthcare'; Recursion Pharmaceuticals, a leading AI-driven drug development company in which Nvidia has invested; and Intuitive Surgical, a specialist in surgical robots, respectively.
In addition, it invests in companies that possess or collaborate on medical AI-related technologies, such as Google, Novartis, Nvidia, and AstraZeneca.
Expectations for the medical AI industry are rapidly spreading, fueled by US President Donald Trump's policy initiative to establish an AI-based digital healthcare system. On July 30, the US Department of Health and Human Services (HHS) and the Office of Government Efficiency (DOGE) signed an agreement at the White House, attended by President Donald Trump, for the construction of an 'AI Digital Healthcare System.' This agreement involved not only big tech companies such as Google, Amazon, and OpenAI, but also healthcare companies such as CVS Health and UnitedHealth, as well as 11 hospitals.
Kim Taewoo, CEO of Hana Asset Management, explained, "The adoption of AI-based digital healthcare systems is accelerating, led by the US government," and added, "I am confident that AI will be utilized across all areas of the medical field as AI technology advances."
In addition, Hana Asset Management will hold an online live webinar titled 'Analysis of the US Medical AI Industry' on August 12, together with Kang Hana, a pharmaceutical/bio analyst. The webinar will cover industry outlooks for the medical AI sector and provide performance analyses of key companies such as Tempus AI and Recursion Pharmaceuticals, which are scheduled to announce their Q2 earnings soon.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
